Anish Thomas
National Cancer Institute (NCI) · National Cancer Institute LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
2
NIH RePORTER
Trial papers
424
PubMed author-name match
Trials
Studies that name Anish Thomas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07328490 · Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerNational Cancer Institute (NCI) · withdrawn · Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma · principal investigator
- Ph1NCT05353439 · Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNational Cancer Institute (NCI) · terminated · Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma · principal investigator
- Ph1NCT05085548 · ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor MalignanciesProDa BioTech, LLC · completed · Advanced Pancreatic Cancer, Solid Tumor Malignancies · principal investigator
- Ph1/Ph2NCT04826341 · A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsNational Cancer Institute (NCI) · completed · HRD Cancer, SCLC, Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT04802174 · Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersNational Cancer Institute (NCI) · active not recruiting · SCLC, Small Cell Cancer, Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT03554473 · M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung CancersNational Cancer Institute (NCI) · completed · Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT03221400 · PEN-866 in Patients With Advanced Solid MalignanciesTarveda Therapeutics · unknown · Carcinoma, Endometrial Adenocarcinoma, Neoplasms · study chair
- Ph1/Ph2NCT02769962 · Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerNational Cancer Institute (NCI) · terminated · Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms · principal investigator
- Ph1/Ph2NCT02487095 · Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersNational Cancer Institute (NCI) · completed · Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma · principal investigator
- N/ANCT01851395 · Rapid Autopsy and Procurement of Cancer TissueNational Cancer Institute (NCI) · terminated · Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma · principal investigator
- Ph1NCT00926640 · A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced CancersNational Cancer Institute (NCI) · completed · Carcinoma Neuroendocrine, Small Cell Lung Carcinoma, Malignant Epithelial Neoplasms · principal investigator
- Ph1NCT00923520 · A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced MalignanciesNational Cancer Institute (NCI) · completed · Renal Cell Carcinoma, Breast Cancer, Colon Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development Therapeutics Branch-Translational Medicine and Therapeutics GroupZICBC012174 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $1,018,780 awarded in 2025Same name and institution; not confirmed by an ID
- Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer TherapiesZIABC011793 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2025 · $4,075,119 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Development of a protein drug for pancreatic cancer treatmentR42CA217482 · NCI · PRODA BIOTECH, LLC · PI Zhi-Ren Liu · fiscal years 2018 to 2019Named on NCT05085548
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 424 PubMed records, and a shared surname and initials can bring in a namesake. All 424 on PubMed
- Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals.Nat Med · 2021777 citationsRCR 51.2
- 678 citationsRCR 30.5
- 368 citationsRCR 9.7
- 341 citationsRCR 11.9
- Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.Cancer Discov · 2017328 citationsRCR 10.8
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell · 2021307 citationsRCR 13.7
- The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia.J Int Neuropsychol Soc · 2000248 citationsRCR 8.2
- 208 citationsRCR 15.5
- Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.Blood · 2019203 citationsRCR 7.9
- A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.Clin Cancer Res · 2014195 citationsRCR 5.5